-
公开(公告)号：US20110059895A1
公开(公告)日：2011-03-10
申请号：US12742076
申请日：2008-11-05
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao
CPC classification number: C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
Abstract translation: 本文公开了用于减少因子9并增加有需要的个体中的凝血时间的反义化合物和方法。 通过施用靶向因子9的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞，血栓栓塞如深静脉血栓形成，肺栓塞，心肌梗死和中风。
-
Patent Agency Ranking
公开(公告)号：US08334372B2
公开(公告)日：2012-12-18
申请号：US12580241
申请日：2009-10-15
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao , Jeffrey R. Crosby , Andrew M. Siwkowski
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao , Jeffrey R. Crosby , Andrew M. Siwkowski
CPC classification number: A61K31/7125 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/727 , A61K31/737 , C07H21/00 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y304/21027
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
Abstract translation: 本文公开了用于减少因子11并在需要其的个体中治疗或预防血栓栓塞并发症的反义化合物和方法。 通过施用靶向因子11的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞和中风。 靶向因子11的反义化合物也可用作预防性治疗，以预防患有血栓形成和栓塞风险的个体。
-
公开(公告)号：US20100298417A1
公开(公告)日：2010-11-25
申请号：US12741959
申请日：2008-11-05
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
IPC: A61K31/7088 , C07H21/04
CPC classification number: C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12Y304/21021 , C12N2310/3525
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cancer, rheumatoid arthritis, and fibrosis.
Abstract translation: 本文公开了用于减少因子7并在需要其的个体中治疗或预防血栓栓塞并发症，过度增殖性疾病或炎性病症的反义化合物和方法。 通过施用靶向因子7的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞，中风，癌症，类风湿性关节炎和纤维化。
-
公开(公告)号：US09029337B2
公开(公告)日：2015-05-12
申请号：US12741959
申请日：2008-11-05
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
IPC: C12N15/11 , C12N15/113
CPC classification number: C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12Y304/21021 , C12N2310/3525
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cancer, rheumatoid arthritis, and fibrosis.
Abstract translation: 本文公开了用于减少因子7并在需要其的个体中治疗或预防血栓栓塞并发症，过度增殖性疾病或炎性病症的反义化合物和方法。 通过施用靶向因子7的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞，中风，癌症，类风湿性关节炎和纤维化。
-
公开(公告)号：US20120214862A1
公开(公告)日：2012-08-23
申请号：US13384327
申请日：2010-07-15
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Chenguang Zhao
IPC: A61K31/712
CPC classification number: C12N15/1137 , C07H21/00 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y304/21021 , C12N2310/3525
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 7 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
Abstract translation: 本文公开了用于减少因子7并在有需要的个体中治疗或预防血栓栓塞并发症的反义化合物和方法。 通过施用靶向因子7的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞和中风。 靶向因子7的反义化合物也可用作预防性治疗，以预防患有血栓栓塞和栓塞风险的个体。
-
公开(公告)号：US20100137414A1
公开(公告)日：2010-06-03
申请号：US12580241
申请日：2009-10-15
Applicant: Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao , Jeffrey R. Crosby , Andrew M. Siwkowski
Inventor： Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao , Jeffrey R. Crosby , Andrew M. Siwkowski
IPC: A61K31/7125 , C07H21/00 , A61K31/7088 , A61P9/10
CPC classification number: A61K31/7125 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/727 , A61K31/737 , C07H21/00 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y304/21027
Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
Abstract translation: 本文公开了用于减少因子11并在需要其的个体中治疗或预防血栓栓塞并发症的反义化合物和方法。 通过施用靶向因子11的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞和中风。 靶向因子11的反义化合物也可用作预防性治疗，以预防患有血栓形成和栓塞风险的个体。
-
-
-
-
-
Search Results
6
records
(took 0.027 seconds)
